In Section A, contributors will obtain unique doses and schedules of oral ABBV-744 pill to determine Safe and sound dosing program. Extra members will be enrolled on the determined monotherapy dosign program. In Phase B, participants will receive oral ruxolitinib and ABBV-744 is going to be presented as "increase-on" therapy. https://douglasm766xit8.bleepblogs.com/profile